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We have screened sera from patients with systemic 
lupus erythematosus for reactivity with RNA tran- 
scribed in vitro using HeLa whole  cell  extracts.  Sera 
from 14 out of 114 patients precipitated an RNA tran- 
scribed by RNA polymerase 111 from a plasmid con- 
taining an Alu family sequence ( i .  e. the repetitive DNA 
sequence that is cut by the Alu restriction enzyme) 
located upstream from the human rG-globin  gene. 
These Alu transcripts were not precipitated by anti- 
La, anti-Sm,  anti-RNP or anti-Ro antibodies, suggest- 
ing that Alu RNA was precipitated by a previously 
undescribed lupus specificity. Analysis of [36S]methio- 
nine-labeled immunoprecipitates indicated that Alu 
RNA binds a protein of about 68 kDa. This protein 
may be Alu specific since three different Alu tran- 
scripts  were precipitated by the anti-Alu sera whereas 
another RNA polymerase 111 transcript, adenovirus VA 
I RNA, was not precipitated by the same sera. 
Sera from patients with systemic lupus  erythematosus and 
related  autoimmune diseases exhibit antibodies directed 
against numerous cellular antigens (see Ref. 1 for review). 
Since the original observation by Lerner  and  Steitz (2) that 
principal classes of these antibodies (anti-RNP,’ anti-La, 
anti-Ro, anti-Sm) recognize small nuclear ribonucleoprotein 
particles, the sera from systemic lupus  erythematosus  patients 
have been used to elucidate the structure of several RNP 
particles (3, 4)  as well as  the potential role of U1-RNP in 
mRNA splicing (5-7). 
The  anti-La class of autoantibodies is believed to recognize 
RNPs formed by RNA polymerase 111 transcripts (3,8). These 
transcripts include precursors to small cellular RNAs such as 
tRNA,  5 S RNA, and 7 S RNA (9, 10) as well as several viral 
RNAs (11-13). In addition the vesicular stomatitis virus 
leader RNP, which is transcribed by a virus-specific RNA 
polymerase, is also precipitated by anti-La sera (14, 15). The 
La antigen seems to bind to  the oligo-U sequence typically 
present at  the 3‘-end of the polymerase 111 transcripts (16). 
The role of the  La antigen in vivo is not known. There were 
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suggestions that La antigen is a transcription factor (9) or 
that  it  is complexed with a  transcription factor (17) since sera 
with anti-La specificity inhibited i n  vitro transcription of 
RNAs transcribed by RNA polymerase 111 (17). However, 
Francoeur  and Mathews (13) reported that i n  vitro transcrip- 
tion of adenovirus VA RNA,  which is precipitated by anti-La 
antibody, could not be inhibited by depletion of the extract 
with anti-La sera. 
We describe here a previously unidentified antibody speci- 
ficity from certain lupus and scleroderma patients,  distinct 
from anti-La,  anti-Ro, anti-RNP,  and  anti-Sm,  that reacted 
with i n  vitro synthesized RNPs containing Alu transcripts 
but did not  precipitate  another RNA polymerase 111 transcript 
synthesized in vitro. The antigen is a  protein which appears 
to bind to  the 5‘ half of the Alu RNA. 
EXPERIMENTAL PROCEDURES 
Whole cell and nuclear extracts were obtained from HeLa cells as 
described by Manley et al. (18) and Dignam et al. (19), respectively. 
Sera were from a bank of frozen samples which had been sent for 
characterization of possible antibodies to extractable nuclear antigens 
and were  from rheumatology patients of the North Carolina Memorial 
Hospital. In most experiments, sera were used without further treat- 
ment. In some instances purified IgG fraction (20) was  used. 
Plasmids A36 (21) and  RBa-1 ((22) a kind gift of Dr. T. Maniatis, 
Harvard University) have been described. Plasmid dl-313 which car- 
ries genes coding for VA I and VA I1 RNA  from adenovirus serotype 
5 was a gift from Dr. Dana Fowlkes, Department of Pathology, 
University of North Carolina. Plasmid U6-13, a subclone of a plasmid 
described previously (23)’ carries  a  truncated copy of an Alu family 
gene. All plasmids were linearized before transcription as indicated 
in Fig. 1. 
In vitro transcription was carried out in a  total volume of 50 ~l as 
described (18). At the end of incubation samples were diluted with 
150 pl of 50 mM Tris-HC1, pH 7.4,  150 mM NaCI,  0.05% Nonidet P- 
40 (Sigma), immunoprecipitated as described by Lerner and Steitz 
(2),  and  the isolated RNA  was analyzed by polyacrylamide gel elec- 
trophoresis (24). 5 ~1 of undiluted serum was  used in each immuno- 
precipitation. 
HeLa cells grown in monolayers were labeled overnight with [%SI 
methionine at  0.5 mCi/ml or with 13H]uridine at 100 pCi/ml. I n  vivo 
labeled cell extracts were prepared and immunoprecipitated as de- 
scribed (25).  [3H]Uridine-labeled RNA was analyzed as above, and 
[35S]methionine-labeled proteins were analyzed by electrophoresis on 
sodium dodecyl sulfate  containing  10% polyacrylamide gels (26) fol- 
lowed  by fluorography. 
RESULTS 
Immunoprecipitation of in Vitro  Transcribed Alu RNA-A 
plasmid carrying both an Alu family sequence and  a fragment 
of the 7”-globin gene  (A36,  Ref. 21) was  used as  a template 
for i n  vitro transcription with HeLa whole  cell extract (18). 
R. Kole, unpublished data. 
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The  structure of the plasmid is shown in Fig. 1. This DNA 
clone allows simultaneous transcription of the Alu RNA 
(RNA polymerase I11 transcript)  and  the human yc-globin 
gene (polymerase I1 transcript). In vitro transcribed RNA was 
precipitated with sera from lupus patients essentially as de- 
scribed by Lerner and  Steitz (2) and analyzed by polyacryl- 
amide gel electrophoresis (24). Fig. 2 shows the results of 
RNA immunoprecipitation  with  a  series of sera from lupus 
and scleroderma patients. 
Certain sera which we have determined to have anti-RNP, 
anti-Sm, anti-Ro, and anti-SCL-70 specificities precipitated 
in vitro transcribed Alu RNA (Fig. 2, lanes 2,  3,  4, and lo ) ,  
suggesting that anti-Alu reactivity is present in  these  sera in 
addition to,  and is distinct from, the major classes of auto- 
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FIG. 1. Structure of the DNA templates. Boxes represent tran- 
scribed genes. Arrows represent the RNA transcribed in uitro. The 
length of the transcripts  in nucleotides is indicated. The size of the 
genes and  the distances between them are not to scale. The DNA 
templates were linearized by cleavage at  the indicated restriction 
sites. 
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FIG. 2. Immunoprecipitation of Alu  RNA transcribed in ui- 
tro from A36 DNA template. RNA was synthesized in vitro and 
immunoprecipitated as described under "Experimental Procedures." 
Electrophoresis was on an 8% urea-polyacrylamide gel (24). The gel 
was autoradiographed overnight at -70 "C with DuPont Lightning 
Plus screen and Kodak XAR-5 film. Lane 1, serum from healthy 
individual; Lanes 2-10, immunoprecipitates by patients' sera; Lanes 
11-13, immunoprecipitates by standard reference lupus sera; specific- 
ity of the sera  is indicated at  the top of the figure. Lane 14, in uitro 
transcribed RNA loaded directly on a gel. Immunoprecipitated RNA 
from whole 50-pl reaction mixture is loaded on  a gel in lunes 1-13. 
One-fourth of this amount is loaded in lune 14. Patients'  initials  are 
indicated at  the top of the figure. The position of yG-globin run-off 
transcript and Alu RNA is indicated. The Alu RNA doublet is due to 
the partial read-through of the RNA polymerase I11 past  the termi- 
nation site (30). N ,  normal human serum; T, in vitro transcribed 
RNA. 
antibodies. This was also supported by the fact that the 
reference anti-La,  anti-Sm, and  anti-RNP sera were anti-Alu 
negative (Fig. 2, lanes 11-13). 
The finding that some anti-La sera did not precipitate Alu 
RNA was surprising, since La  protein has been reported to be 
associated with RNA polymerase I11 transcripts, including 
Alu RNA (3, 8, 9, 10-12, 22). Moreover, it was previously 
found that one anti-La serum (from patient Le, a generous 
gift from Dr. J. Steitz, see also Ref. 22) precipitated Alu RNA 
in  our assay? These  results indicate that sera from certain 
lupus patients contain an anti-Alu antibody that is distinct 
from the major classes of lupus autoantibodies. Furthermore, 
the precipitation of  Alu RNA by the La serum from patient 
Le (22) may have been due to  the presence of this anti-Alu 
antibody rather  than  the  anti-La component. 
The  amount of RNA precipitated with each patient  anti- 
Alu serum was variable. In our experimental conditions the 
most active sera precipitated about 25% of the transcribed 
Alu RNA. As shown in Fig. 2, the intensity of the bands  in 
lanes 2 and 10 is comparable to  that in lane 14. In lane 14, 
however, only one-fourth of the amount of the original reac- 
tion was loaded on the gel. Other  sera precipitated signifi- 
cantly lower amounts of Alu RNA (lunes 3, 4, and 7; lane 7 
appears to be negative but a weak  Alu band could  be clearly 
seen on the original autoradiograph). 
Some of the sera precipitated a labeled band with mobility 
slower than  that of the yG-globin run-off transcript suggest- 
ing  a reactivity with high molecular weight nucleic  acid (lanes 
3 and 9).  The origin of this band is currently under investi- 
gation. It is possible that ribosomal RNA which  was present 
in the whole cell extract was labeled during in vitro transcrip- 
tion and precipitated with anti-ribosomal RNA antibodies 
(27). 
Immunoprecipitation of in Vitro Transcribed Adenovirus 
VA I RNA-We have tested the reactivity of our sera with 
the in vitro synthesized adenovirus VA I RNA that was 
previously shown to be precipitated by anti-La sera (11,  13) 
to determine if  Alu and VA RNPs share common antigenic 
properties. 
We have tested four sera  in this assay. Three of these sera 
contained anti-La antibodies and  the fourth serum (AL) had 
high levels of anti-Alu antibody (Fig. 2, lane 2 ) .  Anti-La sera 
precipitated in vitro transcribed VA I RNA (Fig. 3, lanes 2,3,  
and 5 ) ,  in agreement with the observation of Francoeur and 
Mathews (13)) but did not react with the A36 Alu RNA  (Fig. 
3, lanes 7,8, and 10). In contrast, serum AL,  which contained 
anti-RNP activity (see Figs. 5 and 6), did not precipitate VA 
I RNA (lane 4 )  but did precipitate Alu RNA (lane 9) .  Normal 
human serum was negative in this assay (lanes 1 and 6). 
Phenol-extracted intact Alu RNA was not precipitated by  AL 
serum in the presence or absence of the RNase inhibitor 
RNasin (Promega Biotec), suggesting that a protein antigen 
is required for recognition by the antibody (results not shown). 
The above experiments indicate that Alu RNA binds a 
protein which is not common to all RNA polymerase I11 
transcripts  and  as can be seen from the following experiment 
this protein  binds to RNAs transcribed from other Alu genes. 
Precipitation of Other Alu Transcripts-In addition to Alu 
and VA transcripts described above we have tested two other 
Alu RNAs in our in vitro assay. One Alu sequence is located 
downstream from the human a-globin gene (22, plasmid RBa- 
l), and  the  other plasmid (U6-13) carries  a  truncated copy  of 
an Alu gene from an undetermined region of the human 
genome (23).' The results of the immunoprecipitations are 
R. Kole and S. Weissman, unpublished data. 
Immunoprecipitation of in  Vitro Transcribed Alu RNA 11783 
N RM SS AL  EC N 
1 2 3 4 5 6  
RM SS AL EC 
Alu 
VA 
7 8 9 1 0  
FIG. 3. Immunoprecipitation of  VA I and Alu  RNA by anti- 
La and anti-Alu  sera. Immunoprecipitation and RNA analysis as 
in  Fig. 2. Lunes 1-5, immunoprecipitates of VA I RNA. Lanes 6-10, 
immunoprecipitates of  Alu RNA. 
RBcx-1 A 36 U 6  -13 
RM AL T RM AL T RM AL T 
1 2 3  4 5 6  7 8 9  
FIG. 4. Immunoprecipitation of A h  RNA transcribed from 
different DNA templates. Immunoprecipitation and RNA analysis 
as in Fig. 2. Lunes I, 4, and 7, immunoprecipitation by serum RM, 
an anti-La-containing serum. Lanes 2,5,  and 8, immunoprecipitation 
by serum  AL, an anti-Alu serum. Lanes 3, 6, and 9, RNA transcribed 
presented in Fig. 4. All three Alu transcripts were precipitated 
by serum AL, an anti-Alu serum (lanes 2, 5, and 8). As has 
been shown in Fig.  3, lane 4 ,  serum AL did not precipitate the 
VA RNA. In addition two other anti-Alu sera were  negative 
versus VA I RNA (not shown). Since three Alu transcripts 
were precipitated by anti-Alu sera and a non-Alu transcript, 
VA I, was not precipitated by anti-Alu sera these results 
suggest that  the antigen recognized  by these  sera may  be  Alu 
specific. As expected from previous experiments (Fig. 3, lane 
7) the Alu transcript derived from plasmid A36 was not 
precipitated by serum RM, an  anti-La containing serum (lane 
4 ) .  However,  weak bands of the Alu RNAs derived from RBa- 
1 and U6-13 could be detected in immunoprecipitations with 
this serum (lanes 1 and 7), suggesting a possibility that these 
transcripts bind, albeit weakly, the La antigen in addition to 
the Alu antigen. It is likely that  the differences in the se- 
quences around the transcription termination sites are re- 
sponsible for this difference in binding of the La antigen by 
Alu transcripts (see “Discussion”). 
The  truncated Alu transcript derived from the plasmid U6- 
13 contains 139 base pairs from the 5‘-end of the Alu sequence 
and includes the polymerase I11 promoter. When transcribed 
in vitro, this plasmid gave rise to a transcript about 200 
nucleotides long. The size of the  transcript  as well as  Southern 
blot experiments (not shown) indicated that  the transcript 
initiates at  the 5’-end of the Alu gene and terminates within 
the vector sequences, about 60 nucleotides downstream from 
the 3’ end of the Alu fragment. The fact that  the truncated 
Alu was precipitated by the anti-Alu serum AL suggests that 
the Alu antigen binds to  the 5’ half of the Alu transcript. 
However, the possibility that  this antigen binds to  the down- 
stream vector sequences cannot be  excluded. 
Precipitation of RNA and Proteins  in the in  Vivo Labeled 
Extracts-We have used [35S]methionine and [3H]uridine la- 
beled extracts (25) from HeLa cells to study the immunopre- 
cipitation of the in vivo labeled ribonucleoprotein particles 
and have tested five anti-Alu sera  in these assays. Fig. 5 shows 
immunoprecipitates of a 35S-labeled extract. All five sera 
precipitated a common potein band with an apparent molec- 
ular mass of about 68 kDa (lanes 5-8, and 10, band indicated 
by dots). This band was not observed in the immunoprecipi- 
tates obtained with Alu negative sera (lanes 2-4, 9, 11,  and 
12). Immunoprecipitation of [3H]uridine-labeled extracts by 
the same five anti-Alu sera is shown in Fig. 6. We did not 
detect  any common RNA band precipitated by anti-Alu sera; 
hence the role and association of  Alu antigen in vivo remains 
to be established. 
Analysis of the gels in Figs. 5 and 6 indicates that  the  anti- 
Alu sera,  in  addition to anti-Alu specificity, exhibit anti-RNP 
(Figs. 5 and 6, lanes 5 and 8) ,  anti-Ro (lanes 6, 7, and 10 in 
Fig. 5 and lanes 6, 7, and 9 in Fig. 6) and anti-U2/Ul 
specificities (lane 7 in  both figures). Control Alu-negative sera 
exhibit specificities versus Sm (Fig.  5, lanes 9 and 11 and Fig. 
6, lanes 10 and 12), RNP (Fig.  6, lane 13), La and Ro  (Fig. 5, 
lanes 3 ,9 ,  and 11 and Fig.  6, lanes 3 and l o ) ,  To (Figs. 5 and 
6, lane 4 ) ,  and U2-U1 (Fig. 5, lane 12 and Fig. 6, lane 1 1 )  
antigens. These  results  support the conclusions based on the 
in  vitro experiments that anti-Alu specificity is not associated 
with and is distinct from any known lupus antibody. 
We were unable to detect the 68-kDa band on immunoblots 
(28) using either nuclear (19) or whole  cell extracts (18) as a 
source of the antigen. In  the same experiments Sm and La 
proteins could be easily detected (results not shown). Since 
the 68-kDa band was immunoprecipitated from 35S-labeled 
extracts  in much smaller quantities than La and Sm proteins 
from plasmids indicated at the top of figure,  loaded directly on a gel. (compare bands below  50 kDa in Fig. 5 with the 68-kDa band) 
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FIG. 5. Immunoprecipitation of ["S]methionine in vivo la- 
beled HeLa cell extracts. Immunoprecipitated proteins were ana- 
lyzed by electrophoresis on a 10% sodium  dodecyl sulfate-polyacryl- 
amide gel (26). Lane I, molecular mass markers. Molecular mass is 
indicated  in kilodaltons. Lanes 2-4,9,1 I and 12, immunoprecipitation 
by Alu-negative  sera. Specificities of the control  sera  are  indicated at 
top of the figure. N ,  serum  from a healthy individual. Lanes 5-8 and 
10, immunoprecipitation by anti-Alu sera. A putative Alu antigen 
common to all anti-Alu sera is indicated by dots. Patient initials are 
at the top. 
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FIG. 6. Immunoprecipitation of ['Hluridine-labeled HeLa 
cell extracts. Immunoprecipitation  and  RNA  analysis was as in Fig. 
2. Lane 1, RNA isolated directly  from the extracts and  used as size 
markers. Lanes 2-4 and 10-13, precipitation by Alu-negative  control 
sera.  Sera specificity is indicated at the top. Lanes 5-9, precipitation 
by anti-Alu sera. Patients' initials are indicated at the top of the 
lanes. 
TABLE I 
Prevalence of antidlu  in sera containing other antinuclear antigens 
Known  extractable  nuclear antigen specificities were determined 
bv immunodiffusion  and  comDarison to standard  reference  antisera. 
it is possible that the 68-kDa protein band was lost in a 
somewhat higher background of immunoblots. Alternatively 
it is likely that  the antigen was not recognized by the antibody 
after denaturation and separation on SDS-containing gels 
and subsequent blotting. 
Screening of the Sera for antidlu Specificity-Using the in 
vitro transcription of the A36 plasmid in our assay we have 
screened 114 sera from  selected patients with other  antinu- 
clear antibodies for the ability to precipitate A h  RNA. The 
results of the screening, summarized in Table I, again support 
the observation that  anti-Ah antibody does not correspond 
to any known antibody to established nuclear antigens. There 
was no correlation of anti-Ah with the presence of any of the 
other specificities examined. 
As seen in Table I1 patients with the  anti-Ah antibody 
specificity suffered from  scleroderma or from systemic lupus 
(two patients had discoid lupus and two mixed connective 
tissue disease). No  obvious clinical association with anti-Alu 
antibody was  observed. The antibody was not  a marker for 
scleroderma, as  it was present in only 6 of 19 scleroderma 
sera. Similarly, the antibody was present in a minority of 
systemic lupus erythematosus sera. 
DISCUSSION 
In results presented here 12% of the sera from selected 
patients with autoimmune diseases contained antibodies 
Specificity Number Number of Alu of sera positive 
Anti-Sm 20 3 
Anti-RNP 28 6 
Anti-La 20 1 
Anti-Ro 23  3 
All specificities 114 14 
which precipitated RNA transcribed in vitro from the A h  
family  gene  located upstream from the human yc-globin  gene. 
Two other A h  transcripts were  also precipitated by anti-Ah 
sera. Because the Alu transcripts  are  not uniformly  precipi- 
tated by sera known to contain any of the major  classes of 
lupus autoantibodies, i.e. anti-RNP, -Sm, -La, and anti-Ro, 
anti-Alu most  likely represents a distinct and novel  specific- 
ity. In addition, anti-Alu sera precipitate a 68-kDa protein 
band which is not precipitated by the A h  negative sera further 
suggesting that  anti-Ah is a novel  specificity  recognizing a 
previously unidentified lupus antigen. 
Alu  RNA is transcribed and terminated by  RNA polymerase 
I11 in uitro, and it might be  expected that  this RNA should 
bind La antigen and be precipitable by anti-La antibodies as 
are  other polymerase I11 transcripts. However, it should be 
noted that  the sequence around the termination site of the 
A h  gene in plasmid A36 is 5' CTTATTATT (30); hence the 
transcript derived  from this gene  will have a UU dimer at the 
3'-end. Since it has been  shown that La antigen binds to  the 
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TABLE I1 
Clinical characteristics ofpatients with anti-Alu 
Known nuclear antigen specificities were determined as in Table I. Abbreviations: Ab, antibody; SCL, sclero- 
derma; SLE, systemic lupus erythematosus; DLE, discoid lupus; MCTD, mixed connective tissue disease; N, 
nucleolar antinuclear  antigen (ANA); S, speckled ANA; H, homogeneous ANA; X, unknown precipitin line. RNP, 
Ro, DNA, La, and Sm  denote  appropriate antibody specificity. 
Patient 
initials Age Sex  Diagnosis Ab 
Other Comments 
JHa SCL 
VG 38 F SCL N; RNP Mild myositis 
EJ 43 F  SCL S; Ro Calcinosis; pulmonary fibrosis 
KMcC 50 F SCL H Myositis; pulmonary fibrosis 
AL 40 F SCL RNP; X 
CF 20 F SLE  RNP CNS lupus 
JC 40 M SLE DNA 
ELC 
SWB 63 F MCTD RNP 
GP 24 F SLE H 
J P  35 F SLE Sm; RNP 
MB 46 F SLE  Sm Autoimmune hemolytic anemia 
RJMcC 45 M MCTD Ro; X Myositis; pituitary adenoma 
JLM 60 F  DLE Ro 
Proteinuria; serositis 
37 F  DLE Ro; La 
Hemolytic anemia 
oligo U sequence at  the  3'-end of the polymerase I11 tran- 
scripts (16) and that the binding to longer U oligomers is 
much stronger than binding to dimers  (31)  it is likely that  the 
Alu  RNA sequence was not recognized efficiently by the La 
antigen.  In  contrast, VA I RNA terminates at a sequence 5' 
CUUUU (32)  and,  as expected, was efficiently precipitated by 
anti-La sera. The fact that  an  anti-La serum weakly precipi- 
tated Alu transcripts derived from plasmids RBa-1  and U6- 
13 seems to suggest that these RNAs bind La antigen in 
addition to  the Alu antigen. Since the termination sites of 
these  transcripts  are  not well mapped it is difficult to correlate 
this result with the sequences that might be responsible for 
the weak binding of the La antigen. 
The fact that  La antigen did not bind to A36 Alu RNA 
seems to indicate that binding of La protein to RNA is not 
required for correct transcription  and  termination of at least 
certain polymerase I11 transcripts. However, the possibility 
that  the La protein may act  as  a  transcription  or  termination 
factor by interacting with DNA or other  components of the 
transcription complex cannot be excluded. 
It has been recently suggested that Alu sequences are proc- 
essed pseudogenes for 7 S RNA (29). The 7 S RNA complexed 
with 6 polypeptides forms the signal recognition particle 
(SRP), which participates in the translocation of secretory 
proteins across membranes (33). One of the  SRP polypeptides 
has  a molecular mass of 68 kDa which is similar to  that of 
the common band visible in 35S-labeled anti-Alu immunopre- 
cipitates. However, it  has been shown that  the 68-kDa SRP 
protein  binds to sequences of the 7 S RNA which lack ho- 
mology to Alu sequences (34), making the SRP protein an 
unlikely candidate for the Alu antigen.  In  addition,  anti-Alu 
sera did not precipitate 7 S RNA from the in vivo labeled 
extracts prepared from HeLa cells (see Fig. 6)  or baby hamster 
kidney cells (not shown). 
Another possibility is that Alu antigen is an RNA polym- 
erase 111 transcription factor, analogous to  TFIIIA (35, 36). 
Similar to  the AIu antigen, which binds to Alu RNA and does 
not  bind VA RNA, TFIIIA  binds to  the promoter region in 5 
S RNA but does not  bind to VA RNA (35-37). In our prelim- 
inary  experiments we were unable to inhibit  transcription of 
Alu RNA by pretreating the extracts with anti-Alu sera, 
suggesting that  the Alu antigen is not  a  transcription factor. 
However, due to  the volume limitations  and the presence of 
RNAse in the sera we were not able to ascertain that all of 
the antigen had been removed leaving open the possibility 
that Alu antigen does play a part in transcription. More 
experiments will  be required to establish the identity  and the 
in vivo role of the Alu antigen. 
Two recent reports  (38,39) indicate that a high percentage 
of lupus sera  contain  antibodies  against he erogeneous nuclear 
RNP.  Transcription of the plasmid A36 (21) which has been 
used in this study allows for simultaneous transcription of 
Alu RNA and yc-globin RNA. Globin RNA forms a  hetero- 
geneous nuclear RNP-like particle during transcription in 
vitro (40),' so it could be expected that  this complex will be 
precipitated by some sera. However, none of the 114 sera 
tested precipitated yc-globin RNA in our assay. A few sera 
(Fig. 1, lunes 3 and 9) precipitated  a labeled high molecular 
weight band, but  the origin and identity of this  band is not 
known. 
The significance of the clinical findings regarding the  pa- 
tients which exhibit  anti-Alu antibody is unclear. All of the 
patients with this reactivity had either systemic lupus or 
scleroderma. There was  no apparent common manifestation 
of disease nor was there  any evidence of association of anti- 
Alu with antibodies to  other known nuclear antigens. As the 
sera screened for the presence of anti-Alu were  from a  bank 
of sera known to have antinuclear  antigens, no estimate  can 
be made of the frequency of this specificity in the general 
population. 
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